HIV-associated lipodystrophy: Pathogenesis and clinical features

Advances in Cardiology

Volumn 40, Issue , 2003, Pages 97-104

  Barbara, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIV ASSOCIATED LIPODYSTROPHY; HUMAN; PATHOPHYSIOLOGY; REVIEW;

HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS;

EID: 0242335906     PISSN: 00652326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Carr A, Samaras K, Burton S, et al: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
2. Carr A: HIV lipodystrophy: Risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17(suppl 1):S141-S148.
3. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1-protease inhibitorassociated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351: 1881-1883.
4. Mooser V, Carr A: Antiretroviral therapy-associated hyperlipidemia in HIV disease. Curr Opin Lipidol 2001;12:313-319.
5. Fauvel J, Bonnet E, Ruidavets JB, et al: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001;15: 2397-2406.
6. Assmann G, Schulte H, von Eckardstein K: Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1178-1179.
7. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-20254.
8. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-321.
9. Barbaro G, Klatt EC: Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Des 2003;9:1475-1481.
10. Behrens GM, Stoll M, Schmidt RE: Lipodystrophy syndrome in HIV infection: What is it, what causes it and how can it be managed? Drug Saf 2000;23:57-76.
11. Smith D: Clinical significance of treatment-induced lipid abnormalities and lypodystrophy. J HIV Ther 2001;6:25-27.
12. John M, Nolan D, Mallal S: Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001;6:9-20.
13. Carr A, Hudson J, Chuan J, et al: HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811-1822.
14. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, et al: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-1526.
15. Ruiz L, Negredo E, Domingo P, et al: Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J AIDS 2001;27:229-236.
16. van der Valk M, Kastelein JJP, Murphy RL, et al: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-2414.
17. Volberding P, Murphy R, Barbaro G, et al: The Pavia Consensus Statement. AIDS 2003; 17(suppl 1):S170-S179.